Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Pandite LN"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon LR, Mooser VE, Pandite LN
Publikováno v:
Journal of Clinical Oncology; 6/20/2011, Vol. 29 Issue 18, p2557-2564, 8p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Monk BJ, Pandite LN
Publikováno v:
Journal of Clinical Oncology; 12/20/2011, Vol. 29 Issue 36, p4845-4845, 1p
Autor:
Dharminder Chauhan, Shaji Kumar, Kenneth C. Anderson, Rakesh Kumar, Giovanni Tonon, Steven Legouill, Kenji Ishitsuka, Yu Tsu Tai, Klaus Podar, Teru Hideshima, Martin Sattler, Lini Pandite, Hiroshi Yasui
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 103(51)
A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8053b32b958131aa4513416e2f1f7fe8
https://pubmed.ncbi.nlm.nih.gov/17164332
https://pubmed.ncbi.nlm.nih.gov/17164332
Autor:
Zurita AJ; MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA., Gagnon RC; Bristol-Myers Squibb Company, PO Box 5400, J42-05, Princeton, NJ 08543, USA., Liu Y; Pfizer Translational Oncology, 10646 Science Center Dr, San Diego, CA 92121, USA., Tran HT; MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA., Figlin RA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USA., Hutson TE; US Oncology/McKesson Specialty Health, The Woodlands, TX, USA.; Texas Oncology, Dallas, TX, USA.; Baylor Sammons Cancer Center, Dallas, TX 75246, USA., D'Amelio AM Jr; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA., Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome 00152, Italy., Pandite LN; Adaptimmune LLC, Philadelphia, PA 19112, USA., Heymach JV; MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Publikováno v:
British journal of cancer [Br J Cancer] 2017 Aug 08; Vol. 117 (4), pp. 478-484. Date of Electronic Publication: 2017 Jul 06.
Autor:
Xu CF; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania. chun-fang.2.xu@gsk.com., Johnson T; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Wang X; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Carpenter C; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Graves AP; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Warren L; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Xue Z; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., King KS; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Fraser DJ; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Stinnett S; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Briley LP; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Mitrica I; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Spraggs CF; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Nelson MR; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., Tada H; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania., du Bois A; Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany., Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Kaplowitz N; Keck School of Medicine, University of Southern California, Los Angeles, California., Pandite LN; GlaxoSmithKline Research and Development, Stevenage, UK, Research Triangle Park, North Carolina and King of Prussia, Pennsylvania.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Mar 15; Vol. 22 (6), pp. 1371-7. Date of Electronic Publication: 2015 Nov 06.
Autor:
Xu CF; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Johnson T; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Garcia-Donas J; 1] Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain [2] Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, Rome 00152, Italy., Davis ID; Monash University Eastern Health Clinical School, 5 Arnold Street, Victoria 3128, Australia., Bing N; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., Deen KC; GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA., Xue Z; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., McCann L; GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA., Esteban E; 1] Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain [2] Hospital Universitario Central de Asturias, Calle Carretera de Rubín, Oviedo 33011, Spain., Whittaker JC; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Spraggs CF; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Rodríguez-Antona C; Spanish National Cancer Research Centre and ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Calle de Melchor Fernández Almagro 3, Madrid 28029, Spain., Pandite LN; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., Motzer RJ; Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Publikováno v:
British journal of cancer [Br J Cancer] 2015 Mar 31; Vol. 112 (7), pp. 1190-8. Date of Electronic Publication: 2015 Mar 31.